{"id":"https://openalex.org/W2188731670","doi":null,"title":"VILAZODONE: A NEW TREATMENT FOR MAJOR DEPRESSIVE DISORDER","display_name":"VILAZODONE: A NEW TREATMENT FOR MAJOR DEPRESSIVE DISORDER","publication_year":2012,"publication_date":"2012-01-01","ids":{"openalex":"https://openalex.org/W2188731670","mag":"2188731670"},"language":"en","primary_location":{"id":"mag:2188731670","doi":null,"is_oa":false,"landing_page_url":"http://copnt13.cop.ufl.edu/doty/pep/pharmanote/May2012.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Jennifer Jones","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Jennifer Jones","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13118","display_name":"Psychological Treatments and Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vilazodone","display_name":"vilazodone","score":1.0},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9990000128746033},{"id":"https://openalex.org/keywords/antidepressants","display_name":"antidepressants","score":0.7459999918937683},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.8429999947547913},{"id":"https://openalex.org/keywords/5-ht1a-receptor-partial-agonist","display_name":"5-HT1A receptor partial agonist","score":0.9049999713897705},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8629999756813049},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7549999952316284},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dosage","display_name":"dosage","score":0.9340000152587891},{"id":"https://openalex.org/keywords/clinical-trials","display_name":"clinical trials","score":0.6050000190734863},{"id":"https://openalex.org/keywords/fda-approval","display_name":"FDA approval","score":0.6579999923706055}],"concepts":[{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.8385710716247559},{"id":"https://openalex.org/C2779908668","wikidata":"https://www.wikidata.org/wiki/Q834280","display_name":"Bupropion","level":3,"score":0.6642006635665894},{"id":"https://openalex.org/C2781068410","wikidata":"https://www.wikidata.org/wiki/Q421930","display_name":"Mirtazapine","level":4,"score":0.6604829430580139},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.595281183719635},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5598176717758179},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.5247421860694885},{"id":"https://openalex.org/C2781081902","wikidata":"https://www.wikidata.org/wiki/Q3539074","display_name":"Tricyclic","level":2,"score":0.5182964205741882},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.49475425481796265},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.44138845801353455},{"id":"https://openalex.org/C2780092697","wikidata":"https://www.wikidata.org/wiki/Q7455053","display_name":"Serotonin reuptake inhibitor","level":4,"score":0.4174734950065613},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34801387786865234},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3399033844470978},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3017706274986267},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.21168896555900574},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.15606164932250977},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C2777843972","wikidata":"https://www.wikidata.org/wiki/Q2462253","display_name":"Smoking cessation","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2188731670","doi":null,"is_oa":false,"landing_page_url":"http://copnt13.cop.ufl.edu/doty/pep/pharmanote/May2012.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W11112109","https://openalex.org/W81687552","https://openalex.org/W235373371","https://openalex.org/W1964439201","https://openalex.org/W1973699479","https://openalex.org/W1977947752","https://openalex.org/W1996930866","https://openalex.org/W2018670592","https://openalex.org/W2044334793","https://openalex.org/W2075505106","https://openalex.org/W2102351697","https://openalex.org/W2106983312","https://openalex.org/W2107225963","https://openalex.org/W2107404443","https://openalex.org/W2108262590","https://openalex.org/W2123757779","https://openalex.org/W2128884444","https://openalex.org/W2132895884","https://openalex.org/W2145066076","https://openalex.org/W2148945798","https://openalex.org/W2150408471","https://openalex.org/W2151809600","https://openalex.org/W2156131531","https://openalex.org/W3022401702"],"related_works":["https://openalex.org/W1867705717","https://openalex.org/W1521938669","https://openalex.org/W2107972801","https://openalex.org/W1824075533","https://openalex.org/W2078647070","https://openalex.org/W2051587086","https://openalex.org/W2322790968","https://openalex.org/W2110728963","https://openalex.org/W1990376788","https://openalex.org/W1503094989"],"abstract_inverted_index":{"Volume":[0],"27,":[1],"Issue":[2],"8":[3],"May":[4],"2012":[5],"1":[6],"ajor":[7],"Depressive":[8],"Disorder":[9],"(MDD)":[10],"is":[11,39,64,89,171,222,233],"a":[12,54,172,200,205],"debilitating":[13],"disease":[14,25],"that":[15,50],"affects":[16,26],"patient\u2019s":[17],"overall":[18],"health":[19],"and":[20,69,109,133,138,192,209,248],"quality":[21],"of":[22,30,35,43,72,84,203,207,212,226,230,250],"life.":[23],"This":[24],"13%":[27],"\u2013":[28],"16%":[29],"Americans":[31],"through":[32],"the":[33,67,90,186,224,238],"course":[34],"their":[36,164],"lifetime.":[37],"There":[38],"an":[40],"increased":[41],"risk":[42],"MDD":[44,63,105],"in":[45],"females,":[46],"middle-aged":[47],"persons,":[48],"those":[49,155],"are":[51,58,151,157],"single,":[52],"have":[53],"low":[55],"income,":[56],"or":[57,60],"unemployed":[59],"disabled.":[61],"1,2":[62,100],"diagnosed":[65],"using":[66],"Diagnostic":[68],"Statistical":[70],"Manual":[71],"Mental":[73],"Disorders,":[74],"Fourth":[75],"Edition,":[76],"Text":[77],"Revision":[78],"(DSMIV-TR)":[79],"criteria.":[80],"The":[81,228],"average":[82],"age":[83],"onset":[85,94],"for":[86,154,176,223],"this":[87,231],"disorder":[88],"late":[91],"20s,":[92],"but":[93,150],"may":[95],"occur":[96],"at":[97,116],"any":[98],"age.":[99],"Many":[101],"patients":[102],"suffering":[103],"from":[104],"receive":[106,113],"delayed":[107],"treatment":[108,115,119,174,225],"up":[110],"to":[111,147,159,163,234],"40%":[112],"no":[114],"all.2":[117],"First-line":[118],"options":[120],"include":[121],"selective":[122],"serotonin":[123,127,213],"reuptake":[124,129],"inhibitors":[125,130,141],"(SSRIs),":[126],"norepinephrine":[128],"(SNRIs),":[131],"bupropion,":[132],"mirtazapine.":[134],"Tricyclic":[135],"antidepressants":[136],"(TCAs)":[137],"monoamine":[139],"oxidase":[140],"(MAOIs)":[142],"can":[143],"also":[144],"be":[145],"used":[146],"treat":[148],"MDD,":[149],"usually":[152],"reserved":[153],"who":[156],"unresponsive":[158],"other":[160],"treatments":[161],"due":[162],"unfavorable":[165],"side":[166],"effect":[167],"profile.3,4":[168],"Vilazodone":[169,198],"(Viibryd\u00ae)":[170],"new":[173],"option":[175],"MDD.":[177,227],"It":[178],"was":[179],"approved":[180,220],"on":[181,237],"January":[182],"21,":[183],"2011":[184],"by":[185,189,194],"FDA,":[187],"licensed":[188],"Merek":[190],"KGaA,":[191],"distributed":[193],"Forest":[195],"Labs,":[196],"Inc..":[197],"has":[199],"novel":[201],"mechanism":[202],"action:":[204],"combination":[206],"SSRI":[208],"partial":[210],"agonist":[211],"receptor":[214],"subtype":[215],"1A":[216],"(5-HT1A).":[217],"Its":[218],"only":[219],"indication":[221],"objective":[229],"article":[232],"provide":[235],"information":[236],"pharmacology,":[239],"pharmacokinetics,":[240],"past":[241],"clinical":[242],"trials,":[243],"adverse":[244],"events,":[245],"drug":[246],"interactions":[247],"dosing":[249],"vilazodone.":[251]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}